This risk is the result of traditional and nontraditional CVD risk factors.
2
Predicted and observed CVD-free survival showed good agreement in all validation sets.
3
Heightened risk of CVD is often attributable to treatment with anthracycline chemotherapy.
4
Participants: Participants with self-reported history of established diagnosis of CVD were excluded.
5
Age-associated changes of such cells may enhance the risk of developing CVD.
1
Background: Left ventricular mass offers prognostic information for assessing cardiovasculardisease risk.
2
Background: Education is inversely associated with cardiovasculardisease incidence in developed countries.
3
Context: The risk factors for cardiovasculardisease and erectile dysfunction are similar.
4
Objective: Microalbuminuria is associated with increased risk of cardiovasculardisease and mortality.
5
Background: Moderate alcohol consumers have lower rates of cardiovasculardisease than abstainers.
1
Leading causes of death were due to nutrition and metabolic diseases followed by diseasesofthecirculatorysystem.
2
Diseasesofthecirculatorysystem (mainly acute myocardial infarction) and fractures were the most common reasons for hospitalisation of European patients abroad.
1
Objective: Cigarette smoking is an important modifiable risk factor for cardiovasculardiseases.
2
The risk for developing cardiovasculardiseases was not different between the groups.
3
Background and purpose: PDGF-BB is an angiogenic factor involved in cardiovasculardiseases.
4
Conclusion: Telomere shortening has been reported in several metabolic and cardiovasculardiseases.
5
The Company is principally focused on developing genetically-targeted therapies for cardiovasculardiseases.
Uso de cv disease en inglés
1
Subclinical CVdisease was associated with age and dyslipidemia but not with other risk factors.
2
These effects seem particularly important for reducing risk of CVdisease in patients with the metabolic syndrome.
3
This study provides preliminary data for developing an integrated model of multidisciplinary care for the management of CVdisease.
4
Increasing the understanding of the pathogenesis of various CVdiseases may provide novel therapeutic targets to improve their prevention and treatment.
5
The metabolic syndrome (MS) represents a cluster of cardiovascular (CV ) risk factors associated to CVdisease and type 2 diabetes.
6
Additionally, recent studies suggest that GnRH antagonists may significantly reduce CV risk compared to GnRH agonists, particularly in men with pre-existing CVdisease.
7
Because AstraZeneca's study also looked at patients without established CVdisease, it potentially opens up a larger market that also covers so-called primary prevention.
8
Coronary and CVdisease biomarkers in UWS correlated better with serum than with LS and GS based on group status and measures of time effect.